Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.
These names are now undervalued, despite solid results and good fundamentals.
Doug Kass shares his thoughts on Twitter, Apple and Alphabet.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.